Peter and Louise Havens establish endowed chair for biomedical research at Lankenau
Lankenau Medical CenterMay 9, 2017Research News
(Wynnewood, Pa.) – Lankenau Medical Center, part of Main Line Health, recently held a celebratory dinner at the Walter and Leonore Annenberg Conference Center for Medical Education at Lankenau Medical Center to mark the establishment of The Havens Chair for Biomedical Research, generously endowed by Peter and Louise Havens. The first incumbent chair holder is George C. Prendergast, PhD, president and CEO, Lankenau Institute for Medical Research (LIMR). An endowed chair is a distinguished position that is bestowed upon an exceptional Lankenau leader.
The Havens Chair was created through the combination of a $1 million gift from Peter and Louise Havens, leading Lankenau benefactors, that was matched by a $1 million grant from the Lankenau Medical Center Foundation through its $1 million+ matching initiative. Margaret Foti, PhD, MD, CEO of the American Association for Cancer Research, the oldest cancer research organization in the world, was guest presenter.
“We are fortunate to have nine donor-endowed chair positions that exemplify the hope, excellence and innovation that are palpable at Lankenau Medical Center,” said Phil Robinson, president, Lankenau Medical Center. “The value of endowed chairs underscores the importance of scholarship in both the practice of medicine and society at large. The Havens Endowed Chair for Biomedical Research will serve to advance critical scientific research at Lankenau for generations to come.”
Peter and Louise Havens have a storied family history at Lankenau that goes back several generations. Peter Havens’ great-grandfather, Hermann Hessenbruch, was the president of Lankenau from 1901–1913, following the passing of John D. Lankenau. Peter’s grandmother, Florence Dreer Hessenbruch, was the first president of the Women’s Board, as well as the founder of the Deaver Auxiliary and the Gift Shop at Lankenau. During Peter Havens’ tenure, LIMR researchers have made myriad breakthroughs, including advancing a promising new cancer therapy using “IDO inhibitors” (experimental drugs originally discovered by Drs. George Prendergast and Alexander Muller, associate professor at LIMR). IDO inhibitors that are now in multiple clinical trials have been named among the ‘top 10’ experimental treatments that could cure cancer by the National Cancer Institute.
“It is an honor to celebrate the exceptional largesse of Mr. and Mrs. Havens to Lankenau,” added Robinson. “We especially thank Mr. Havens for his dedicated work as chairman of the board of the Lankenau Institute for Medical Research, in addition to his service as a trustee on the Main Line Health and Lankenau Boards. As chairman of its boards, Mr. Havens has ably guided LIMR, in partnership with Dr. George Prendergast, into an exciting new era of possibilities.”
About Main Line Health
Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.
At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.
About Lankenau Medical Center
Lankenau Medical Center, a member of Main Line Health, is recognized as a national leader in advancing new options to diagnose and treat illness, protect against disease and save lives. Located on a 93-acre campus just outside of Philadelphia, Lankenau Medical Center is a 389-bed, not-for-profit teaching hospital that includes one of the nation’s leading cardiovascular centers; the Lankenau Institute for Medical Research, one of the few freestanding hospital-associated research centers in the nation; and the Annenberg Conference Center for Medical Education, that trains over 100 new physicians each year through nationally ranked residency and fellowship programs. Lankenau has received both regional and national recognition for its excellence in providing state-of-the-art, quality care. Lankenau Medical Center has been named among the top 10 hospitals in Pennsylvania and top five in the Philadelphia metro area in U.S. News & World Report’s Best Hospitals 2019–20, and was ranked as high-performing in abdominal aortic aneurysm repair, aortic valve surgery, colon cancer surgery, gastroenterology & GI surgery, geriatrics, heart bypass surgery, heart failure, hip replacement, knee replacement, lung cancer surgery and nephrology. Lankenau has achieved The Joint Commission’s Gold Seal of Approval for stroke care and breast cancer care and is one of the nation’s Top Performing Hospitals for heart attack, heart failure, pneumonia and surgical care. Lankenau has also been ranked for multiple years as one of the top 50 cardiovascular hospitals in the nation by Truven Health Analytics. Lankenau has also earned the highest distinction for excellence in nursing care, the American Nurses Credentialing Center Magnet® designation.